Analyst picks & changes

Genentech Inc.


Several analysts raised their ratings and/or earnings estimates on GNE after presentation of data from a Phase II study of


DNase in chronic bronchitis and a company conference call last week indicating that first-quarter results would be above expectations.

David Molowa of Bear, Stearns raised his rating to "strong buy"

Read the full 559 word article

How to gain access

Continue reading with a
two-week free trial.